RxDoctor Payments DataLook up a doctor →

Julio Davalos, MD

Urology · Glen Burnie, MDNPI 1548343064

Payments from drug & device makers

$502,809in general payments, 2019–2025

Across 699 payments — averaging $719.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$400K
  • KARL Storz Endoscopy-america$53K
  • Lumenis Ltd.$15K
  • Johnson & Johnson$15K
  • Calyxo, Inc.$13K
  • Sumitomo Pharma America, Inc.$612
  • plus $6K from 50 others

What the payments were for

  • Consulting fees$112,35023%
  • Speaking & faculty fees$335,54468%
  • Travel & lodging$24,5265%
  • Food & beverage$17,4314%
  • Education$1580%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$502,809 in reported general payments places this provider in the 95th percentile of 274 urology providers in Maryland.

See all urology providers in Maryland

Medicare billing

Part B allowed, 2024
$283,180
Medicare patients
457
Services billed
2,359

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Potassium Citrate ErPotassium Citrate352$30,136
MyrbetriqMirabegron23$13,185
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst17$1,358
Tamsulosin Hcl120$1,220
Cefdinir81$1,174
Chlorthalidone64$954
Trospium Chloride12$873
Oxybutynin Chloride ErOxybutynin Chloride28$621
Alfuzosin Hcl ErAlfuzosin Hcl26$515
Finasteride17$298
Terazosin Hcl14$189
Potassium Chloride30$188
Ondansetron OdtOndansetron51$186
Allopurinol12$154
Oxycodone Hcl63$132

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$529$13,18523 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 274 urology providers in Maryland.

Other urology in Glen Burnie

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →